Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q6P2Q9
UPID:
PRP8_HUMAN
Alternative names:
220 kDa U5 snRNP-specific protein; PRP8 homolog; Splicing factor Prp8; p220
Alternative UPACC:
Q6P2Q9; O14547; O75965
Background:
Pre-mRNA-processing-splicing factor 8, also known as PRP8 homolog, plays a pivotal role in pre-mRNA splicing, participating in multiple spliceosomal complexes. It acts as a scaffold, ensuring the precise assembly of spliceosomal proteins and snRNAs, crucial for the accurate removal of introns from pre-mRNA. Its interaction with the 5' and 3' splice sites underscores its importance in the splicing process.
Therapeutic significance:
The association of Pre-mRNA-processing-splicing factor 8 with Retinitis pigmentosa 13, a retinal dystrophy, highlights its clinical relevance. Understanding its role could pave the way for innovative therapeutic strategies targeting spliceosomal dysfunctions in pigmentary retinopathies.